Arbutus Biopharma

Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022

Retrieved on: 
Monday, October 31, 2022
Webcast, Internet, Investor, Name, Maintenance, Patient, Chronic obstructive pulmonary disease, Arbutus Biopharma, NASDAQ, FDA, Telephone, COPD, Pharmaceutical industry

DUBLIN, Oct. 31, 2022 /PRNewswire/ --Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022.

Key Points: 
  • DUBLIN, Oct. 31, 2022 /PRNewswire/ --Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022.
  • An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.
  • A replay of the webcast will be available on Theravance Biopharma's website for 30 days through December 7, 2022.
  • Theravance Biopharma, Inc.'s overarching purpose and goal as a biopharmaceutical company is focused on delivering Medicines that Make a Difference in people's lives.

Efficacy Testing Global Industry Report 2022: Growing Preference for Outsourcing Efficacy Testing to Drive Market Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022
Science, Health, Other Science, Other Health, Adoption, Time, Use, Government, Growth, Laboratory, Final good, CAGR, Cosmetics, Cosmetic industry, Region, Awareness, Incidence, Conditional sentence, ADC, Medical device, Microbiology, USD, Contamination control, Personal care, Pharmaceutical industry, Pharma, Arbutus Biopharma

The "Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global efficacy testing market is projected to reach USD 423 million by 2027 from USD 315 million in 2022, at a CAGR of 6.1% during the forecast period.
  • The growth of this market is mainly driven by the increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability; growing preference for outsourcing efficacy testing; and the rising adoption of the QbD approach.
  • The high growth potential in emerging markets will provide growth opportunities for players operating in the efficacy testing market.

SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event

Retrieved on: 
Wednesday, September 21, 2022
Sophia, Therapy, Acceleration, Algorithm, Investor relations, Twitter, Machine learning, Entrepreneurship, Research, Neoplasm, U.S. Securities and Exchange Commission, Oncogene, LinkedIn, Sophia Genetics, Company, Health, ECHO, Partnership, Immunotherapy, IVD, Forward-looking statement, Patient, Intelligence, Memorial Sloan Kettering Cancer Center, Cancer, CEO, Arbutus Biopharma, Technology, Instagram, Solution, Rolling circle replication, Drug development, MSK, GENETICS, DNA, Hospital, Multimedia, Precision medicine, Mobile phone, Medical device, Management, Medical imaging, Facebook

BOSTON and GENEVA, Sept. 21, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.

Key Points: 
  • One takeaway from the event was SOPHiA GENETICS' acceleration into the Biopharma space, which opens the door for new opportunities for market growth.
  • SOPHiA GENETICS recently announced a memorandum of understanding to enter into a collaboration with Memorial Sloan Kettering Cancer Center ("MSK").
  • The collaboration agreements will also allow SOPHiA GENETICS' global network of healthcare providers access to MSK's proprietary tumor sequencing tests such as MSK-IMPACT , for analyzing tumors.
  • "Our vision is to expand access to world-class data, including to our current network, which contributes to the collective intelligence of the SOPHiA GENETICS platform," said Philippe Menu, M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.

Fingerpaint Group Continues Global Expansion With New Europe-Based Role at Leaderboard Branding

Retrieved on: 
Thursday, September 8, 2022
D, The Best Place to Be, DE, Global Awards, Arbutus Biopharma, Collection, Health, LinkedIn, Organization, Creativity, Leaderboard, Brand Institute, Inc. (magazine), Twitter, B2B, Clio Awards, Clinical trial, Pharmaceutical industry, Hunting, Telly, Fingerpaint, Facebook

SARATOGA SPRINGS, N.Y., Sept. 8, 2022 /PRNewswire/ -- Fingerpaint Group, an integrated collection of healthcare companies, continues to expand its global footprint with the hiring of Dan Hunt, managing director, Europe at Leaderboard Branding, a Fingerpaint Group company.

Key Points: 
  • "Fingerpaint Group's commitment to the global pharma community has never been stronger," said Bill McEllen, global president, Fingerpaint Group, which includes Leaderboard Branding.
  • "This new role is key for Leaderboard Branding, as it solidifies its place as the premiere global naming and branding leader for biopharma."
  • Fingerpaint Group is composed of Fingerpaint, 1798, Leaderboard Branding, MedThink Communications, MedThink SciCom, Engage, and Fingerpaint Multicultural.
  • Leaderboard Branding, a Fingerpaint Group company, is a global naming and branding firm that delivers strategic insights and world-class creativity to every client, on every engagement.

Heritage Global Partners Awarded New Global Vendor Contract With Pfizer

Retrieved on: 
Tuesday, September 6, 2022
Professional Services, Health, Finance, Asset Management, Pharmaceutical, Biotechnology, 119th Fighter Squadron, 120th Fighter Squadron, Program, NASDAQ, MRO, Sale, Aerospace, Arbutus Biopharma, Food, Senior, HGP, Electronics, Clinical trial, United Kingdom, Metalworking, Acquisition, Asset, Auction, Fine chemical, Aviation, Pfizer, Semiconductor, Plastic, Printing, Chemical substance

Heritage Global Partners (HGP), a worldwide leader in asset advisory and auction services, and a subsidiary of Heritage Global Inc. (NASDAQ: HGBL), announced today that it has been re-selected as Pfizers global vendor for asset disposition services relating to laboratory equipment.

Key Points: 
  • Heritage Global Partners (HGP), a worldwide leader in asset advisory and auction services, and a subsidiary of Heritage Global Inc. (NASDAQ: HGBL), announced today that it has been re-selected as Pfizers global vendor for asset disposition services relating to laboratory equipment.
  • Securing the contract award is a product of a comprehensive and competitive bid process among multiple potential vendors.
  • Information on those auctions can be found at www.hgpauction.com
    Heritage Global Partners, Inc. ("HGP") is a subsidiary of Heritage Global Inc. (NASDAQ: HGBL).
  • Heritage Global Inc. (HG) values and monetizes industrial & financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets.

Theravance Biopharma to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 6, 2022
The Crossing (Star Trek: Enterprise), View, NASDAQ, Morgan Stanley, Maintenance, IST, Chronic obstructive pulmonary disease, Fireside chats, Multimedia, Conference, Company, FDA, COPD, Investor, Arbutus Biopharma, Webcast, Name, Patient, Pharmaceutical industry

Replay of the webcast will be archived on the Company's website for 30 days.

Key Points: 
  • Replay of the webcast will be archived on the Company's website for 30 days.
  • Theravance Biopharma, Inc.'s overarching purpose and goal as a biopharmaceutical company is focused on delivering Medicines that Make a Difference in people's lives.
  • In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI(revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
  • THERAVANCE BIOPHARMA, THERAVANCE, and the Cross/Star logo are registered trademarks of theTheravance Biopharmagroup of companies (in theU.S.and certain other countries).

Think Research Reports Q2 and First Half 2022 Results, Highlighted by Strong Revenue Growth and Continued Cost Synergies

Retrieved on: 
Monday, August 29, 2022
Software, Depreciation, COVID-19, Mission statement, Research, CEO, EBITDA, Government, Achievement, Solution, Pharmacy, Net income, IFRS, Arbutus Biopharma, Beedi, Conversation, Intelligence, Organization, Indian stock exchange, Company, Convertible, Nursing, SEDAR, Acquisition, Growth, Leonora O'Brien, Marketing, Patient, Pharmaceutical industry, Video game, Renewable energy, Bank, Security (finance), Thought

Further, Think is increasingly winning larger deals and we are confident that our current trajectory is aligned with the Company's near and longer-term growth and profitability expectations."

Key Points: 
  • Further, Think is increasingly winning larger deals and we are confident that our current trajectory is aligned with the Company's near and longer-term growth and profitability expectations."
  • Subsequent to the quarter-end, Think was able to recognize parts of the delayed revenue and anticipates that this segment will experience a recovery in revenue in the latter part of the second half.
  • Adjusted EBITDA Margin2(as defined herein) was negative 9% in Q2 compared to negative 13% in Q2 2021.
  • Think also made payments of $1.6 million on lease liabilities and $1.6 million for finance costs in the first half of 2022.

QPS FURTHER ENHANCES ITS GLOBAL MEDICAL, REGULATORY AND BIOTECH CRO SERVICES CAPABILITIES

Retrieved on: 
Friday, August 26, 2022
DMPK, Research, Neuropharmacology, Technology transfer, Arbutus Biopharma, Leadership, FDA, Regulatory affairs, Medication, Toxicology, QPS, Clinical trial, Industry, Health, Growth, Drug development, GCP, CRO, Fine chemical, Pharma, Biotechnology

QPS LLC expands capabilities in Global Medical Affairs, Regulatory Affairs and Biotech Clinical Research Services.

Key Points: 
  • QPS LLC expands capabilities in Global Medical Affairs, Regulatory Affairs and Biotech Clinical Research Services.
  • Heather Messenger, Sr. Vice President, Head of GlobalBiotech Services, Sarah Cross, Executive Director, Head of Global Medical Affairs and Kimberley Buytaert-Hoefen,Executive Director, Head of Global Regulatory Affairs.
  • Ms. Messenger who joins QPS with over 26 years of experience across Biotech, BioPharma and CRO sectors, will be taking the lead in expanding QPS clinical execution services and capabilities, with a focus on Biotech clients.
  • These new executives will ensure that QPS has the skills and capabilities to fully implement global Pharma and Biotech drug development projects.

Profitable growth continues: Exyte with remarkable 6M/2022 results and uplifted year-end outlook

Retrieved on: 
Tuesday, August 16, 2022
API, EBIT, CEO, CFO, Growth, EMEA, AT, Workforce, Wacker Chemie, EBITDA, Engineering, Data center, Arbutus Biopharma, List of life sciences, AT&S, MIT, APAC, Massachusetts Institute of Technology, Active ingredient, RNA transfection, Flowers, Renewable energy, Fine chemical, Exyte, Pfizer

In the first half of 2022, Exyte recorded an increase of almost 50 percent year-on-year both in sales and order intake.

Key Points: 
  • In the first half of 2022, Exyte recorded an increase of almost 50 percent year-on-year both in sales and order intake.
  • Exyte's profitability further improved resulting in an adjusted EBITDA of 222 million (6M/2021: 136million) and adjusted EBIT of 202 million (6M/2021: 122 million).
  • With 6.0 percent, the adjusted EBIT margin is also 0.6 percentage points higher compared to previous year (6M/2021: 5.4percent).
  • "We are pleased with our increased sales as well as the robust growth in incoming orders in the first six months of 2022," says Dr. Wolfgang Bchele, CEO of Exyte.

Profitable growth continues: Exyte with remarkable 6M/2022 results and uplifted year-end outlook

Retrieved on: 
Tuesday, August 16, 2022
API, EBIT, CEO, CFO, Growth, EMEA, AT, Workforce, Wacker Chemie, EBITDA, Engineering, Data center, Arbutus Biopharma, List of life sciences, AT&S, MIT, APAC, Massachusetts Institute of Technology, Active ingredient, RNA transfection, Flowers, Renewable energy, Fine chemical, Exyte, Pfizer

In the first half of 2022, Exyte recorded an increase of almost 50 percent year-on-year both in sales and order intake.

Key Points: 
  • In the first half of 2022, Exyte recorded an increase of almost 50 percent year-on-year both in sales and order intake.
  • Exyte's profitability further improved resulting in an adjusted EBITDA of 222 million (6M/2021: 136million) and adjusted EBIT of 202 million (6M/2021: 122 million).
  • With 6.0 percent, the adjusted EBIT margin is also 0.6 percentage points higher compared to previous year (6M/2021: 5.4percent).
  • "We are pleased with our increased sales as well as the robust growth in incoming orders in the first six months of 2022," says Dr. Wolfgang Bchele, CEO of Exyte.